News

TargaZyme, Inc. Announces  Receipt of An SBIR Award from the National Institute of Dental and Craniofacial Research For the Development of TZ 101 Treated Mesenchymal Stem Cells for Treatment of Oral Mucositis San Diego, CA August 26, 2014 – TargaZyme, Inc. (formerly America Stem Cell, Inc.)  a clinical-stage biopharmaceutical company developing novel enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund  the  development of genetically-modified mesenchymal stem cells treated with Targazyme’s lead product, TZ101 for treatment of oral mucositis. This SBIR award is from the

TargaZyme, Inc. Awarded SBIR Grant from National Eye Institute San Antonio, TX July 31, 2014 -- TargaZyme, Inc. (formerly America Stem Cell, Inc.) a clinical- stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund its program for a novel cell-based restorative approach to treat diabetes- related retinopathy. This SBIR award is from the National Eye Institute and Targazyme will be collaborating with Dr. Maria Grant from the Department of Ophthalmology at Indiana University School of Medicine to conduct the research. Retinal

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board San Diego, CA  June 3, 2014  -- TargaZyme, Inc. (formerly America Stem Cell, Inc. or the “Company”), a clinical-stage biopharmaceutical company developing enzyme platform technologies/products  to improve efficacy outcomes for cell therapy and cancer immunotherapy,  announced today that it has appointed Christopher Calhoun to its Business Advisory Board. Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer. Lynnet Koh, Chairman & CEO of  TargaZyme, Inc., stated “Mr. Calhoun is a visionary entrepreuneur, a proven public company CEO with a successful track record

San Antonio, TX   March 4, 2014  -- Targazyme, Inc. (formerly America Stem Cell, Inc., the “Company”) announced today that is has appointed Mark W. Schwartz, Ph.D. to the Company’s Board of Directors. Dr. Schwartz will serve the Company as an independent member of the Board.    As an independent director, Dr. Schwartz will assist in the Company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets.  With the appointment of Dr.

San Antonio, TX   February 5, 2014  -- Targazyme, Inc. (formerly America Stem Cell, Inc.) has been selected to present at the 2014 BIO CEO & Investor Conference being held in New York City on February 10-11, 2014.  The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Targazyme is a privately held clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy.  Targazyme will be presenting in the oncology track for private companies to some of the most influential members

Reports Interim Phase I/IIa Trial Results for TZ101, a Novel Enzyme Treatment to Enhance Stem Cell Targeting/Engraftment for Improved Cancer Patient Clinical Outcomes SAN ANTONIO, TX DEC 18 2013. America Stem Cell, Inc. (ASC) today announces that it has changed its name to Targazyme, Inc. (www.old.targazyme.com). The new name reflects the company’s family of enzyme products aimed at improving cell targeting and engraftment for better efficacy outcomes in stem cell and regenerative medicine. Phase I/IIa results of Targazyme’s lead product, TZ101, were presented at the American Society of Hematology meeting in New Orleans (Popat et al. Abstract #691, Dec 9).

SAN ANTONIO TX DEC 4, 2013. America Stem Cell, Inc. (ASC) today announced that three presentations will be made at the upcoming American Society of Hematology (ASH) meeting in New Orleans, LA December 7-10, 2013 on its lead product, ASC-101. ASC-101 is currently undergoing evaluation in a dual umbilical cord blood transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome at The University of Texas MD Anderson Cancer Center. To date, 16 patients have been transplanted with cord blood that was treated with ASC-101 immediately prior to transplant. On the basis of interim data, ASC received clearance from the U.S. Food and Drug Administration

San Francisco, CA, October 1, 2013 – America Stem Cell, Inc (ASC) announced that Lynnet Koh, CEO will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, Calif. "ASC was founded with the vision to make stem cell transplantation and cell therapy safer and more efficacious for patients. The profound efficacy and safety results from our current Phase I/IIa trial at M.D. Anderson Cancer Center with

SAN ANTONIO, TX JANUARY 7, 2013. America Stem Cell, Inc (ASC) today announced that it has been awarded an Advanced Technology Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health. This grant will be led by Dr. Leonard Miller, VP Preclinical Research at ASC, in collaboration with Dr. Larry Sherman at the Oregon National Primate Research Center, Oregon Health & Science University (OHSU). Dr. Sherman’s lab has over 15 years of extensive experience in multiple models of demyelinating diseases such as multiple sclerosis (MS), and in the application of